On September 2, 2024 Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company") reported that it will host two live webcasts on September 5, 2024 (Press release, MEDIAN Technologies, SEP 2, 2024, View Source [SID1234646271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the recent release of results of the eyonis LCS REALITY study, Fredrik Brag, CEO and Founder of Median Technologies, will offer further insights into the significance of eyonis LCS and discuss the next steps for Median’s novel Software as a Medical Device.

September 5, 2024 – 4:00 pm CEST / 10:00 am EDT (English)
September 5, 2024 – 6:00 pm CEST / 12:00 pm EDT (French)

Webcast replays will be available on Median’s corporate website shortly after the live sessions.